Login to Your Account



Seagen's hold in AML dams up early trials but phase III going ahead

By Randy Osborne
Staff Writer

Tuesday, December 27, 2016

Much talked-about at this year's ASH meeting, the CD33-targeting ADC SGN-CD33A from Seattle Genetics Inc. faltered as the FDA put clinical holds on phase I and phase I/II trials in AML.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription